Skip to content
10-Q

Quarterly Report

Oncology Institute, Inc. DFPH TOI TOIIW

0001799191-26-000010

← back to feed
Filed
May 7, 2026 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q1 2026 · Apr 30, 2026 99.98M sh
Shares Diluted Q1 2026 · Mar 31, 2026 101.8M sh
Shares Diluted Q1 2026 · Mar 31, 2025 77.1M sh
Capex Q1 2026 · Mar 31, 2026 $1.04M
Capex Q1 2026 · Mar 31, 2025 $328K
Operating Cash Flow Q1 2026 · Mar 31, 2026 −$2.22M
Operating Cash Flow Q1 2026 · Mar 31, 2025 −$4.99M
Long Term Debt Q1 2026 · Mar 31, 2026 $78.61M
Long Term Debt Q1 2026 · Dec 31, 2025 $77.4M
Stockholders Equity Q1 2026 · Mar 31, 2026 −$16.29M
Stockholders Equity Q1 2026 · Dec 31, 2025 −$15.72M
Stockholders Equity Q1 2026 · Mar 31, 2025 $5.07M
Stockholders Equity Q1 2026 · Dec 31, 2024 $3.59M
Current Liabilities Q1 2026 · Mar 31, 2026 $79.35M
Current Liabilities Q1 2026 · Dec 31, 2025 $70.96M
Total Liabilities Q1 2026 · Mar 31, 2026 $184.52M
Total Liabilities Q1 2026 · Dec 31, 2025 $180.38M
Current Assets Q1 2026 · Mar 31, 2026 $116.86M
Current Assets Q1 2026 · Dec 31, 2025 $112.75M
Total Assets Q1 2026 · Mar 31, 2026 $168.23M
Total Assets Q1 2026 · Dec 31, 2025 $164.66M
Eps Diluted Q1 2026 · Mar 31, 2026 −$0.02
Eps Diluted Q1 2026 · Mar 31, 2025 −$0.21
Eps Basic Q1 2026 · Mar 31, 2026 −$0.02
Eps Basic Q1 2026 · Mar 31, 2025 −$0.21
Sga Expense Q1 2026 · Mar 31, 2026 $28.21M
Sga Expense Q1 2026 · Mar 31, 2025 $25.38M
Net Income Q1 2026 · Mar 31, 2026 −$2.49M
Net Income Q1 2026 · Mar 31, 2025 −$19.59M
Operating Income Q1 2026 · Mar 31, 2026 −$6.51M
Operating Income Q1 2026 · Mar 31, 2025 −$9.91M
Revenue Q1 2026 · Mar 31, 2026 $147.44M
Revenue Q1 2026 · Mar 31, 2025 $104.41M